Frontier Bio, currently raising on Wefunder, is attempting something audacious:

Big promises. But unlike many preclinical biotech startups, Frontier Bio is already generating revenue - $5.5M in cumulative sales to date.

That alone makes it worth a closer look.

Despite massive advances in medicine, two major bottlenecks remain.

Roughly 90% of drugs that pass animal studies fail in human trials.

That’s an enormous destruction of capital for pharma companies investing in next-gen medicine. Beyond the economic incentives to move away from animal testing, there are also strong consumer & regulatory forces pushing the shift.

Amid animal cruelty concerns, both the NIH and FDA have both signaled support for reducing animal testing in favor of human tissue platforms.

There is an estimated $2.1B global market for in-vitro human tissue models (in-vitro = lab-grown human tissues tested outside the body).

Frontier Bio is already selling into that market.

For small blood vessels, surgeons face two flawed options:

Meanwhile:

The vascular graft market alone is projected at ~$15B in the U.S., with dialysis access representing a ~$3B subset.

Frontier Bio’s bet?

If you can engineer functional blood vessels, you lay the foundation for full organ engineering. Here’s their path to get there:

Frontier Bio has already provided human tissue models and services to:

They’ve completed 25+ projects and secured contracts up to $1.1M for custom tissue R&D. All told, they’ve accumulated $5.5M in sales from this ‘first-step’ offering.

That revenue is important because it helps fund the company’s clinical trials, de-risking their long-term goals.

Now for the more speculative - and potentially massive - upside.

Frontier Bio is developing a tissue-engineered vascular graft that:

They start with an off-the-shelf scaffold (a tube-like structure that cells can attach to and grow on). During surgery, they isolate stem cells from the patient and seed those cells onto the scaffold in real time.

By doing this at the bedside, they bypass:

That’s strategically important and can drastically lower the cost to administer.

If vascular grafts are the beachhead, organs are the endgame.

Blood vessels are the foundational infrastructure of every organ. You can’t build a functional kidney, liver, lung, or heart without first solving vascularization — the ability to reliably grow living blood vessels that integrate into the body.

Frontier Bio’s long-term thesis is that by mastering tissue-engineered vascular grafts, they are building the biological plumbing required for lab-grown, transplantable organs.

In the U.S., more than 100,000 people sit on transplant waitlists at any given time. The economic burden is enormous — and the human cost even greater. Tragically, 13 people die every day waiting for an organ donation match.

If Frontier Bio can prove that their bedside-seeded grafts safely remodel into living vessels in humans, it opens the door to progressively more complex tissue engineering.

Frontier Bio is in the early stages but seeing no signs yet that their approach won’t work. Most recently, a test’s initial findings are really encouraging:

It’s far too early to declare victory, but it’s real preclinical implant data that spark hope in the science.

Frontier Bio is engaging the FDA early and targeting dialysis access as their beachhead indication.

If clinical trials fail or FDA approval doesn’t materialize, the vascular graft thesis collapses.

Frontier Bio still brings in revenue, and depending on growth/margins we could expect a 2x–4x revenue multiple.

If Frontier scaled the tissue model business to:

However these multiples could expand significantly if an acquirer believes the underlying technology can be leveraged further or utilized elsewhere.

Frontier Bio is currently allowing the public to invest, so at this stage lots of scenarios are plausible, from total loss (always a possibility with early-stage companies) to moderate gains.

Assume Frontier Bio:

The U.S. vascular graft market is roughly $10B–$15B annually, with dialysis access alone representing ~$3B.

If Frontier captures 5-10% of the vascular graft market, I could reasonably expect them to attract a valuation between $2-$5B.

That alone would represent a massive potential outcome for early backers.

Now we enter the moonshot.

Over 100,000 Americans currently need organ transplants. The economic burden of transplantation and long-term care runs into the tens of billions annually.

Let’s model just kidneys - the largest transplant category.

If Frontier eventually produced:

That’s $4B in annual revenue.

At 5x–8x revenue (typical for scaled biotech platforms) we could see a $20B–$32B valuation.

If multiple organs (kidney, liver, lung) were commercialized - we’re talking potential $50B+ and a 2,000x return.

Now before you open up Zillow and adjust the budget range slider all the way to the max, I want to caution that this is highly speculative - but mathematically plausible if clinical and regulatory execution is flawless.

Some of the risks that Frontier bio will encounter are:

This is early-stage biotech risk and total loss of capital is possible. But if you want exposure to asymmetric returns with a small portion of your portfolio, this is one I would consider checking out.

I really like that they have a crawl → walk → run setup to get them from current revenues to their moonshot goals. Momentum is pivotal in business, and engineering a sequential roadmap like this delivers increasing confidence & compounding success at each successful advancement.

If you would like more information on Frontier Bio, check out the link below!

Related Reads from CROWDSCALE